RadNet, Inc. (RDNT) - Stock Analysis
Last updated: Apr 5, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Positive EBITDA ⢠Elevated leverage ⢠Rich multiples RDNT generates healthy EBITDA and FCF with a large cash buffer but faces recurring small net losses, high leverage, heavy capex/intangibles, and rich valuation that leave little downside protection.
Price Behavior
Key Price Behavior Insights: ⢠Downtrend confirmed ⢠Trading at low ⢠Resistance cluster Support Level: $54.79 (next psychological support $50.00) Resistance Level: $61â$64 Over the last month the stock dropped ~18% to the period low of $54.79, showing clear bearish momentum and trading near short-term support with key resistance around $61â$64.
Sentiment & News
Key News Insights: ⢠Imaging momentum ⢠AI ramp ⢠M&A activity RadNet is showing accelerating outpatient imaging volumes and scaling its DeepHealth AI/digital-health agenda while pursuing acquisitions, JV deals and partnerships amid active capital allocation and a recent insider sale.
AI Summary
RadNet should be revalued as a hybrid cashâgenerative imaging platform with concentrated upside tied to nascent digitalâhealth/AI commercializationâinvestors must value both steady FCF from accelerating advanced imaging and the binary upside (and execution risk) of TechLive/DeepHealth/Gleamer rather than treating it as a pure rollâup. Key actionable monitorables: evidence of repeatable enterprise software bookings and clear deleveraging trajectories (or failure on either should prompt a material downgrade); reclaiming $61â$64 would signal stabilization.
Description
RadNet, Inc. operates a network of outpatient diagnostic imaging centers across multiple U.S. states, providing services such as MRI, CT, PET, mammography and other multimodality imaging procedures. The company also supplies imaging IT systems, including picture archiving and communication solutions, and has developed software tools to support radiologist interpretation in areas including mammography, lung and prostate cancer. Founded in 1981 and headquartered in Los Angeles, RadNet owned and managed 347 centers as of December 31, 2021.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 8 | Sep 15 | RDNT | RadNet, Inc. | RadNet shows strong Q2 operational momentum with record revenue and EBITDA growth, raised full-year guidance, expanding reimbursement streams, and technical momentum with a ~36% surge over 21 trading days; near-term price upside possible above resistance at ~$73, despite high leverage and valuation risks. | Closed | +4.2% |